Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle

NCT01303094 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01303094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
August 9, 2018
Enrollment
53 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma, uterine sarcoma